Amoy Diagnostics Co Ltd (300685 SHE) stock market data APIs

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a comprehensive genomic profiling assay; AmoyDx BRCA Pro panel, covers various protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes; AmoyDx handle classic NGS panel, detects multiple gene mutations in cancer patients for treatment; and AmoyDx essential NGS panel, detects EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET genes in patients with non-small cell lung cancer and colorectal cancer using FFPE or liquid biopsy samples. It also provides AmoyDx handle HRR NGS panel for detection of somatic and germline variants; AmoyDx pan lung cancer PCR panel, a tissue-based real-time qPCR assay for in vitro diagnostics; AmoyDx myeloid blood cancer panel; AmoyDx comprehensive panel solutions; AmoyDx PD-L1 (E1L3N) assay; and AmoyDx handle melanoma NGS panel solutions. In addition, the company offers ALK gene fusions and ROS1 gene fusions, multi-gene mutations, EML4-ALK fusion gene, EGFR/ALK/ROS1 mutations, MET mutation, HER2 mutation, RET gene fusions, KRAS mutation, KRAS/NRAS mutations, NRAS mutation, KRAS/NRAS/BRAF mutations, BRAF mutation, PIK3CA five mutations, microsatellite instability, PIK3CA mutation, human papillomavirus genotyping, JAK2 mutation, TERT/HRAS mutations, EGFR 29 mutations, EGFR mutation, ROS1 gene fusions, NTRK gene fusions, BRAF V600 mutations detection kits, as well as DNA and RNA extraction kits under the Super-ARMS and AmoyDx names. The company was founded in 2008 and is based in Xiamen, China.